AZN.UK

12,076

-1.15%↓

AZN.UK

12,076

-1.15%↓

AZN.UK

12,076

-1.15%↓

AZN.UK

12,076

-1.15%↓

AZN.UK

12,076

-1.15%↓

Search

GlaxoSmithKline PLC

Suletud

SektorTervishoid

1,473 0.27

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1458.5

Max

1476.5

Põhinäitajad

By Trading Economics

Sissetulek

-126M

1.6B

Müük

470M

8B

P/E

Sektori keskmine

17.44

35.733

Aktsiakasum

0.465

Dividenditootlus

4.34

Kasumimarginaal

20.611

Töötajad

68,629

EBITDA

139M

3.2B

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+7.86% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

4.34%

3.13%

Järgmine tulemuste avaldamine

29. okt 2025

Järgmine dividendimakse kuupäev

9. okt 2025

Järgmine aktsia dividendi kuupäev (ex-date)

13. nov 2025

Turustatistika

By TradingEconomics

Turukapital

1.5B

59B

Eelmine avamishind

1472.73

Eelmine sulgemishind

1473

Uudiste sentiment

By Acuity

28%

72%

79 / 371 Pingereas Healthcare

GlaxoSmithKline PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

30. juuli 2025, 06:50 UTC

Tulu

GSK Upbeat on Guidance After Specialty Medicines Boost Sales

18. juuli 2025, 09:39 UTC

Suurimad hinnamuutused turgudel

GSK Shares Drop After FDA Committee Vote Leaves Cancer-Drug Comeback in Doubt

2. juuni 2025, 10:49 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Theravance Shares Rise Premarket on Sale of Trelegy Royalties

14. mai 2025, 11:01 UTC

Omandamised, ülevõtmised, äriostud

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion - Update

14. mai 2025, 06:39 UTC

Omandamised, ülevõtmised, äriostud

GSK Buys Liver-Disease Treatment From Boston Pharmaceuticals for Up to $2 Billion

12. mai 2025, 09:36 UTC

Suurimad hinnamuutused turgudel

Global Pharma Stocks Fall as Trump Plans to Cut Drug Prices

30. juuli 2025, 09:08 UTC

Market Talk
Tulu

GSK Results Look Solid, But Benefit From Temporary Effects -- Market Talk

30. juuli 2025, 06:06 UTC

Tulu

Correct: GSK PLC 2Q EPS 35.5p

30. juuli 2025, 06:00 UTC

Tulu

GSK PLC 2Q EPS 35.5p

30. juuli 2025, 06:00 UTC

Tulu

GSK PLC 2Q Pretax Pft GBP1.89B

30. juuli 2025, 06:00 UTC

Tulu

GSK PLC 2Q Net Pft GBP1.44B

30. juuli 2025, 06:00 UTC

Tulu

GSK PLC 2Q Adj EPS 46.5p

30. juuli 2025, 06:00 UTC

Tulu

GSK PLC 2Q Turnover GBP7.99B

30. juuli 2025, 06:00 UTC

Tulu

GSK PLC 2Q Pre-items, Pretax Pft GBP2.5B

30. juuli 2025, 06:00 UTC

Tulu

GSK PLC 2Q Oper Pft GBP2.02B

28. juuli 2025, 10:51 UTC

Market Talk

U.S.-EU Tariff Deal, Earnings Could Keep Pharma Rally Going -- Market Talk

18. juuli 2025, 09:05 UTC

Kuumad aktsiad

Stocks to Watch Friday: Netflix, Norfolk Southern, Amex -- WSJ

7. juuli 2025, 15:00 UTC

Omandamised, ülevõtmised, äriostud

GSK Completes Acquisition of Efimosfermin

2. juuni 2025, 10:00 UTC

Omandamised, ülevõtmised, äriostud

Theravance Biopharma Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225M

15. mai 2025, 15:20 UTC

Peamised uudised

New Allegations About Timing of Pfizer Covid Vaccine Passed to House Panel -- WSJ

14. mai 2025, 06:08 UTC

Omandamised, ülevõtmised, äriostud

GSK PLC to Buy Efimosfermin from Boston Pharmaceuticals

14. mai 2025, 06:03 UTC

Omandamised, ülevõtmised, äriostud

GSK PLC: Deal Includes Potential Success-Based Milestone Payments of $800M

14. mai 2025, 06:03 UTC

Omandamised, ülevõtmised, äriostud

GSK PLC to Pay $1.2B Upfront

14. mai 2025, 06:03 UTC

Omandamised, ülevõtmised, äriostud

GSK to Buy Efimosfermin for up to $2B

14. mai 2025, 06:00 UTC

Omandamised, ülevõtmised, äriostud

GSK to Buy Efimosfermin

12. mai 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

12. mai 2025, 07:20 UTC

Market Talk

Pharma Shares Face Risks From Trump's Pricing Plans -- Market Talk

30. apr 2025, 08:54 UTC

Market Talk
Tulu

GSK Investors Turn to U.S. Policy Outlook After Solid Results -- Market Talk

30. apr 2025, 07:49 UTC

Market Talk
Tulu

GSK's Specialty Meds Sustain Growth, Blenrep Comeback Remains Key -- Market Talk

30. apr 2025, 07:06 UTC

Market Talk
Tulu

GSK Outperforms Expectations Despite RSV Vaccine Setback -- Market Talk

Võrdlus sarnastega

Hinnamuutus

GlaxoSmithKline PLC Prognoos

Hinnasiht

By TipRanks

7.86% tõus

12 kuu keskmine prognoos

Keskmine 1,582.83 GBX  7.86%

Kõrge 2,170 GBX

Madal 1,290 GBX

Põhineb 13 Wall Streeti analüütiku instrumendi GlaxoSmithKline PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

13 ratings

2

Osta

8

Hoia

3

Müü

Sentiment

By Acuity

79 / 371 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
help-icon Live chat